

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

### **VOLUNTARY ANNOUNCEMENT**

#### **FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION CLINICAL TRIAL OF TaurusTrio™ TRANSCATHETER AORTIC VALVE REPLACEMENT SYSTEM IN CHINA**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has enrolled the first patient of the multi-center registration clinical trial for TaurusTrio™ transcatheter aortic valve replacement (“**TAVR**”) system (the “**System**”), the licensed-in Trilogy™ Heart Valve System for aortic regurgitation (“**AR**”) from JenaValve Technology, Inc. (“**JenaValve**”). The first implant has been successfully completed by Professor Yongjian Wu and Professor Guangyuan Song in Beijing An Zhen Hospital, Capital Medical University on July 26, 2023. The registration clinical trial of the System is a single-arm, prospective, multi-center study. It is designed to assess the safety and efficacy of the System in treating patients with native symptomatic severe AR, who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. The results of this clinical trial will be included in the Company’s future submission of registration application to the National Medical Products Administration (the “**NMPA**”).

In June 2023, the System was formally accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA. As of the date of this announcement, no transfemoral TAVR product for AR has been approved by the NMPA.

Reference is made to the Company's announcement dated January 14, 2022. The Group obtained an exclusive license from JenaValve for developing, manufacturing and commercializing Trilogy™ Heart Valve System in the Greater China region. Reference is also made to the Company's announcement dated May 15, 2023. On May 12, 2023, the successful completion of the first two commercial implants with the Trilogy™ Heart Valve System took place in Hong Kong.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusTrio™ TAVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, July 31, 2023

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.*